<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951754</url>
  </required_header>
  <id_info>
    <org_study_id>100358</org_study_id>
    <nct_id>NCT02951754</nct_id>
  </id_info>
  <brief_title>Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder</brief_title>
  <official_title>Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coordination for the Improvement of Higher Education Personnel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methylphenidate (MPH) is the first-line pharmacological treatment for adults with
      Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable
      interindividual variability regarding the dose required, tolerability and response rates to
      MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment
      outcomes in ADHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methylphenidate (MPH) is the most prescribed psychostimulant for children and adults with
      Attention-Deficit/Hyperactivity Disorder (ADHD). Meta-analyses and systematic reviews have
      shown that MPH is safe and efficacious in attenuating the core symptoms of ADHD, promoting
      overall clinical improvement. However, many patients still do not show an appropriate
      clinical response to the MPH treatment and there is considerable interindividual variability
      regarding the dose required, tolerability and response rates to MPH. Therefore, it is
      essential to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Anticipated">December 2032</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported changes in severity of ADHD symptoms</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Swanson, Nolan and Pelham Rating Scale - Version IV (SNAP-IV) adapted to adults.
Assessment points at baseline, 6 weeks, 3 months, 6 months and 1 year of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported changes in severity of oppositional defiant disorder symptoms</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Swanson, Nolan and Pelham Rating Scale - Version IV (SNAP-IV) adapted to adults.
Assessment points at baseline, 6 weeks, 3 months, 6 months and 1 year of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatrist's judgment of improvement of patient's symptoms</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Clinical Global Impression - Improvement scale (CGI-I). Assessment points at baseline, 6 weeks, 3 months, 6 months and 1 year of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maintenance of ADHD diagnosis</measure>
    <time_frame>1yr</time_frame>
    <description>Assessed by Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS).
Assessment points at baseline, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in side effects</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Barkley's Stimulants Side Effects Rating Scale. Assessment points at baseline, 6 weeks, 3 months, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in measures of anxiety</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Beck Anxiety Inventory (BAI). Assessment points at baseline, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in measures of depression</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Beck Depression Inventory (BDI). Assessment points at baseline, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in scores of mood disorders</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Mood Disorder Questionnaire (MDQ). Assessment points at baseline, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in insomnia problems</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Insomnia Severity Index (ISI). Assessment points at baseline, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in scores of physical activity</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by International Physical Activity Questionnaires (IPAQ). Assessment points at baseline, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in measures of quality of life</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Adult ADHD Quality of Life Questionnaire (AAQoL). Assessment points at baseline, 6 months and 1 year of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in measures of functional impairment in the main contexts of patient's life</measure>
    <time_frame>1yr</time_frame>
    <description>Evaluated by Sheehan Disability Scale (SDS). Assessment points at baseline, 3 months, 6 months and 1 year of treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>IR-MPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate-release Methylphenidate</intervention_name>
    <description>Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects</description>
    <arm_group_label>IR-MPH</arm_group_label>
    <other_name>Ritaline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  White Brazilian of European descent

          -  Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition, (DSM-IV) diagnostic criteria for ADHD

          -  Eligibility to immediate-release MPH (IR-MPH) treatment

        Exclusion Criteria:

          -  Contraindication for IR-MPH use

          -  Current stimulant treatment

          -  Evidence of a clinically significant neurological disease that might affect cognition
             (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)

          -  Current or past history of psychosis

          -  Estimated intelligence quotient score lower than 70
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugênio H Grevet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugênio H Grevet, MD, PhD</last_name>
    <phone>+55 51 3359-8094</phone>
    <email>ehgrevet@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claiton HD Bau, MD, PhD</last_name>
    <phone>+55 51 33086718</phone>
    <email>claiton.bau@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugênio H Grevet, MD, PhD</last_name>
      <phone>+55 51 3359-8094</phone>
      <email>ehgrevet@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Claiton HD Bau, MD, PhD</last_name>
      <phone>+55 51 33086718</phone>
      <email>claiton.bau@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004 Feb;24(1):24-9.</citation>
    <PMID>14709943</PMID>
  </reference>
  <reference>
    <citation>Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2014 Sep 18;(9):CD005041. doi: 10.1002/14651858.CD005041.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD005041.</citation>
    <PMID>25230710</PMID>
  </reference>
  <reference>
    <citation>Castells X, Cunill R, Capellà D. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2013 Mar;69(3):347-56. doi: 10.1007/s00228-012-1390-7. Epub 2012 Sep 16. Review.</citation>
    <PMID>22983311</PMID>
  </reference>
  <reference>
    <citation>Retz W, Retz-Junginger P. Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S35-43. doi: 10.1007/s00406-014-0542-4. Epub 2014 Sep 18. Review.</citation>
    <PMID>25231833</PMID>
  </reference>
  <reference>
    <citation>Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006 Nov;28(11):1892-908. Review.</citation>
    <PMID>17213010</PMID>
  </reference>
  <reference>
    <citation>Swanson JM, Schuck S, Porter MM, Carlson C, Hartman CA, Sergeant JA, Clevenger W, Wasdell M, McCleary R, Lakes K, Wigal T. Categorical and Dimensional Definitions and Evaluations of Symptoms of ADHD: History of the SNAP and the SWAN Rating Scales. Int J Educ Psychol Assess. 2012 Apr;10(1):51-70.</citation>
    <PMID>26504617</PMID>
  </reference>
  <reference>
    <citation>Brod M, Johnston J, Able S, Swindle R. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006 Feb;15(1):117-29.</citation>
    <PMID>16411036</PMID>
  </reference>
  <reference>
    <citation>Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011 May 1;34(5):601-8.</citation>
    <PMID>21532953</PMID>
  </reference>
  <reference>
    <citation>Gomes-Oliveira MH, Gorenstein C, Lotufo Neto F, Andrade LH, Wang YP. Validation of the Brazilian Portuguese version of the Beck Depression Inventory-II in a community sample. Rev Bras Psiquiatr. 2012 Dec;34(4):389-94.</citation>
    <PMID>23429809</PMID>
  </reference>
  <reference>
    <citation>Gorenstein C, Andrade L. Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Braz J Med Biol Res. 1996 Apr;29(4):453-7.</citation>
    <PMID>8736107</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Adults</keyword>
  <keyword>treatment</keyword>
  <keyword>Methylphenidate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

